Keyphrases
Therapeutic Implications
100%
Clinical Significance
100%
Clinical Treatment
100%
Myelofibrosis
100%
Peripheral Blood Counts
66%
Myeloproliferative Neoplasms
50%
Hematopoietic Stem Cells
33%
Splenomegaly
33%
Unmet Medical Need
16%
Systemic Symptoms
16%
Therapeutic Potential
16%
Overactivation
16%
Clinical Manifestations
16%
Clinical Phenotype
16%
Pathological Features
16%
Effective Treatment
16%
Hematological Malignancies
16%
Janus Kinase 2 (JAK2)
16%
Clinical Heterogeneity
16%
Prognostic Implications
16%
Driver mutations
16%
JAK-STAT Pathway
16%
Ruxolitinib
16%
Constitutional Symptoms
16%
Cytopenia
16%
Bone Marrow Fibrosis
16%
Inflammatory Cytokine Response
16%
Frontline Therapy
16%
Transfusion Support
16%
BCR-ABL1
16%
Therapeutic Limitations
16%
Myeloproliferation
16%
Fedratinib
16%
Medicine and Dentistry
Myelofibrosis
100%
Splenomegaly
28%
Hematopoietic Cell
28%
Inflammatory Cytokine
14%
Cytokine Release
14%
Janus Kinase
14%
Somatics
14%
Hematologic Malignancy
14%
Ruxolitinib
14%
Cytopenia
14%
Myeloproliferative Neoplasm
14%
Constitutional Symptoms
14%
Myeloproliferative Disorder
14%
Fedratinib
14%
Biochemistry, Genetics and Molecular Biology
Blood Cell Count
100%
Hematopoietic Cell
50%
Janus Kinase
25%
Inflammatory Cytokine
25%
Ruxolitinib
25%
Cytokine Release
25%